Clinical-stage Biopharmaceutical Company Announces $3.2M Registered Direct Offering

GT Biopharma, Inc. (NASDAQ: GTBP) recently announced a major development with the entry into definitive securities purchase agreements for a registered direct offering priced at-the-market under Nasdaq rules. The company disclosed that it has secured the purchase and sale of 740,000 shares of its common stock at a purchase price of $4.35 per share, totaling approximately $3.2 million in gross proceeds before deducting placement agent’s fees and other offering expenses. $GT Biopharma(GTBP.US)$